Angiogenic molecules in Hodgkin's disease: Results from sequential serum analysis

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 1, 2006, Pages 161-170

  Passam, F H ^a,e   Alexandrakis, M G ^b   Moschandrea, J ^c   Sfiridaki, A ^d   Roussou, P A ^a   Siafakas, N M ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d Venizelion General Hospital   (Greece)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Angiogenesis; Hepatocyte growth factor; Hodgkin's lymphoma; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 2; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 6; PREDNISONE; PROCARBAZINE; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEQUENTIAL ANALYSIS;

EID: 33646231503     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/205873920601900116     Document Type: Article

References (51)

1. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182.
2. Folkman J., K. Watson, D. Ingher and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58.
3. Manghi M. 2000. Angiogenesis and angiogenic mediators in hematological malignancies. Br. J. Haematol. 111:43.
4. Salven P. 2001. Angiogenesis in lymphoproliferative disorders. Acta Haematol. 106:184.
5. Aguayo A., H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Kolle, Z. Estrov, S. O'Brien, M. Keating, E. Freireich and M. Albitar. 2000. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240.
6. Alexandrakis M., F. Passam, C. Pappa, J. Damilakis, G. Tsirakis, E. Kandidaki, E. Stathopoulos and D. Kyriakou. 2005. Serum evaluation of angiogenic cytokines basic fibroblast growth factor, hepatocyte growth factor and tumor necrosis factor-α in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int. J. Immunopathol. Pharmacol. 18:287.
7. Bairey O., Y. Zimra, E. Kaganovsky, M. Shaklai, E. Okon and E. Rabizadeh. 2000. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med. Oncol. 17:314.
8. Ribatti D., A. Vacca, B. Nico, M. Fanelli, L. Roncali and F. Dammacco. 1996. Angiogenesis spectrum in the stroma of B-cell non Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur. J. Haematol. 56:45.
9. Vacca A., D. Ribatti, L. Ruco, F. Giacchetta, B. Nico, F. Quondamatteo, R. Ria, M. Iurlaro and F. Dammacco. 1999. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer 79:965.
10. Passalidou E., M. Stewart, M. Trivella, G. Steers, G. Pillai, A. Dogan, I. Leigh, C. Hatton, A. Harris, K. Gatter and F. Pessella. 2003. Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. Br. J. Cancer 88:553.
11. Salven P., A. Orpana, L. Teerenhovi and H. Joensuu. 2000. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712.
12. Yao L., S. Pike, J. Setsuda, J. Parekh, G. Gupta, M. Raffeld, E. Jaffe and G. Tosato. 2000. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96:1900.
13. Streubel B., A. Chott, D. Huber, M. Exner, U. Jager, O. Wagner and I. Schwarzinger. 2004. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351:250.
14. Mostafa L., D. Jones and D. Wright. 1980. Mechanism of the induction of angiogenesis by human neoplastic lymphoid tissue: studies on the chorioallantoic membrane (CAM) of the chick embryo. J. Pathol. 132:191.
15. Lister T., D. Crowther, S. Sutcliffe, E. Glatstein, G. Canellos, R. Young, S. Rosenberg, C. Coltman and M. Tubiana. 1989. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwold meeting. J. Clin. Oncol. 7:1630.
16. Hasenclever D. and V. Diehl. 1998. A prognostic score for advanced Hodgkin's diseases. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 339:1506.
17. Jucker M., A. Gunther, G. Gradl, C. Fonatsch, G. Krueger, V. Diehl and H. Tesch. 1994. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk. Res. 18:7.
18. Skibinski G., A. Skibinska and K. James. 2001. Hepatocyte growth factor (HGF) protects c-met-expressing Burkitt's lymphoma cell lines from apoptotic death induced by DNA damaging agents. Eur. J. Cancer 37:1562.
19. Teofili L., A. Di Febo, F. Pierconti, N. Maggianao, M. Bendandi, S. Rutella, A. Cingolani, N. Di Renzo, P. Musto, S. Pileri, G. Leone and L. Larocca. 2001. Expression of the c-met protooncogene and its ligand, hepatocyte growth factor, in Hodgkin's disease. Blood 97:1063.
20. Giles F., J. Vose, K. Do, M. Johnson, T. Manshouri, G. Bociek, P. Bierman, S. O'Brien, H. Kantarjian, J. Armitage and M. Albitar. 2004. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk. Res. 28:595.
21. Bierman P., J. Lynch, R. Bociek, V. Whalen, A. Kessinger, J. Vose and J. Armitage. 2002. The international prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann. Oncol. 13:1370.
22. Doussis-Anagnostopoulou I., K. Talks, H. Turley, P. Debnam, D. Tan, G. Mariatos, V. Gorgoulis, C. Kittas and K. Katter. 2002. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin -Reed-Stenberg cells in Hodgkin's disease. J. Pathol. 197:677.
23. Yokote T., T. Akioka, S. Oka, S. Nakayama, T. Yamano, S. Hara, M. Tsuji and T. Hanafusa. 2004. Vascular endothelial growth factor and interleukin 6 expression by Hodgkin/Reed Stenberg cells. Br. J. Haematol. 125:1.
24. Foss H., I. Araujo, G. Demel, H. Klotzbach, M. Hummel and H. Stein. 1997. Expression of vascular endothelial growth factor in lymphomas and Castleman disease. J. Pathol. 183:44.
25. Hazar B., S. Paydas, S. Zorludemir, B. Sahin and I. Tuncer. 2003. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk. Lymphoma 44:2089.
26. Aref S., M. Mabed, K. Zalata, M. Sakrana and H. El Askalany. 2004. The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome. Leuk. Lymphoma 45:499.
27. Niitsu N., M. Okamoto, H. Nakamine, T. Yoshino, J.Tamaru, S. Nakamura, M. Higashihara and M. Hirano. 2002. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 68:91.
28. Dankbar B., T. Padro, R. Leo, B. Feldmann, M. Kropff, R. Mesters, H. Serve, W. Berdel and J. Kienast. 2000. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630.
29. Yoo S., D. Bae, J. Ryoo, H. Kim, G. Park, C. Cho, C. Chae and W. Kim. 2005. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J. Immunol. 174:5846.
30. Nakahara H., J. Song, M. Sugimoto, K. Hagihara, T. Kishimoto, K. Yoshizaki and N. Nishimoto. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48:1521.
31. Sone H., M. Sakauchi, A. Takahashi, H. Suzuki, N. Inoue, K. Iida, H. Shimano, H. Toyoshima, Y. Kawakami, Y. Okuda, K. Matsuo and N. Yamada. 2001. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci. 96:1861.
32. Webb N., M. Bottomley, C. Watson and P. Brenchley. 1998. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF in clinical disease. Clin Sci. 94:395.
33. Hormbrey E., P. Gillespie, K. Turner, C. Han, A. Roberts, D. Mc-Grouther and A. Harris. 2002. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis. 19:651.
34. Banks R., M. Forbes, S. Kinsey, A. Stanley, E. Ingham, C. Walters and P. Selby. 1998. Release of the angiogenic cytokine vascular endothelial growth factor from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 77:956.
35. Salven P, A. Orpana and H. Joensuu. 1999. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 5:487.
36. Musolino C., A. Alonci, G. Bellomo, B. Loteta, E. Quartarone, D. Gangemi, E. Massara and L. Calabro. 2004. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur. J. Haematol. 72:416.
37. Verstovsek S., H. Kantarjian, A. Aguayo, T. Manshouri, E. Freireich, M. Keating, E. Estey and M. Albitar. 2001. Significance of angiogenin plasma concentrations in patients with acute myeloid leukemia and advanced myelodysplastic syndrome. Br. J. Haematol. 114:290.
38. Bertolini F., M. Paolucci, F. Peccatori, S. Cinieri, A. Agazzi, P. Ferrucci, E. Cocorocchio, A. Goldbirsch and G. Martinelli. 1999. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br. J. Haematol. 106:504.
39. Olson K., S. Verselis and J. Fett. 1998.Angiogenin is regulated in vivo as an acute phase protein. Biochem. Biophys. Res. Comm. 242:480.
40. Ahmad S., W. Liu, Y. Jung, F. Fan, N. Reinmuth, C. Bucana and L. Ellis. 2001. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92:1138.
41. Etoh T., H. Inoue, S. Tanaka, G. Barnard, S. Kitano and M. Mori. 2001. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 61:2145.
42. Tanaka F., S. Ishikawa, K. Yanagihara, R. Miyahara, Y. Kawano, M. Li, Y. Otake and H. Wada. 2002. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 62:7124.
43. Benharroch D., I. Prinsloo, R. Apte, T. Yermiahu, D. Geffen, I. Yanai-Inbar and J. Gopas. 1996. Interleukin-1 and tumor necrosis factor-alpha in the Reed-Sternberg cells of Hodgkin's disease. Correlation with clinical and morphological "inflammatory" features. Eur. Cytokine Netw. 7:51.
44. Metkar S., K. Naresh, P. Manna, V. Srinivas, S. Advani and J. Nadkarni. 2000. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia. Am. J. Hematol. 65:105.
45. Warzocha K., J. Bienvenu, P. Ribeiro, I. Moullet, C. Dumontet, E. Neidhardt-Berard, B. Coiffier and G. Salles. 1998. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br. J. Cancer 77:2357.
46. Jucker M., H. Abts, W. Li, R. Schindler, H. Merz, A. Gunther, C. von Kalle, M. Schaadt, T. Diamantstein and A. Feller. 1991. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 77:2413.
47. Reynolds G., L. Billingham, L. Gray, J. Flavell, S. Najafipour, J. Crocker, P. Nelson, L. Young and P. Murray. 2002. Interleukin 6 expression by Hodgkin/Reed-Stenberg cells is associated with the presence of B symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br. J. Haematol. 118:195.
48. Kurzrock R., J. Redman, F. Cabanillas, D. Jones, J. Rothberg and M. Talpaz. 1993. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 53:2118.
49. Seymour J., M. Talpaz, F. Hagemeister, F. Cabanillas and B. Kurzrock. 1997. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am. J. Med. 102:21.
50. Robak T., A. Gladalska, H. Stepien and E. Robak. 1998. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7:347.
51. Wellby M., J. Kennedy, K. Pile, B. True and P. Barreau. 2001. Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism 50:463.